

DECISIONS WITHOUT A SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT (decisions approved on medicines committee ICB directors' authority)					
NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/guidance relevance	Recommendation	Commissioning & financial implications	Decision
<p><a href="#">TA916: Bimekizumab for treating active psoriatic arthritis</a></p> <p>04/10/2023</p> <p><b>Commissioning: ICS</b></p>	04/10/23	RED drug for other NICE TA approved indications.	Add to formulary as a RED drug in this indication with a link to TA916.	<p>Bimekizumab has been recommended through the NICE cost comparison process, NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication.</p> <p>NICE expect the resource impact of implementing the recommendations in England will be less than approximately £8,800 per 100,000 population.</p> <p>This is because the technology is a further treatment option and is available at a similar price to the current treatment options. Bimekizumab works in a similar way to ixekizumab and secukinumab, and would be offered to the same population.</p> <p>Bimekizumab and the other treatment options have discounts that are commercial in confidence.</p> <p>A resource impact template is provided for completion at a local level. This is because there are numerous treatment options that are recommended by NICE for treating active psoriatic arthritis.</p>	Approved by NENC ICB Chief Pharmacist 19.10.23.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Green+ Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.